Clustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remission by Yehua Yu et al.
Yu et al. Journal of Translational Medicine 2014, 12:18
http://www.translational-medicine.com/content/12/1/18RESEARCH Open AccessClustered precursors in bone marrow sections
predict early relapse in patients with acute
myeloid leukemia within hematologic remission
Yehua Yu†, Zhentian Wu†, Jing Zhang, Yuanmei Zhai, Yinghua Yuan, Sihong Liu, Hui Wang and Jun Shi*Abstract
Background: Bone marrow (BM) aspiration is largely used for relapse assessment in acute myeloid leukemia (AML).
It remains unclear what roles that BM trephine biopsy plays on relapse assessment.
Methods: Bone marrow (BM) sections during complete remission (CR) from 60 acute myeloid leukemia (AML)
patients were retrospectively analyzed. Computer image processing technology was performed for detection of the
distance between precursors and endosteum, and density of precursors was also calculated under light microscopic
image. Immunohistochemistry was used to identify the immunophenotype of clustered precursors.
Results: Except for single and double precursors, there existed clustered precursors of 3-5 cells during CR. Here,
we demonstrated that clustered precursors, but not single and double precursors, were useful in risk factor of
relapse. Area under the receiving operator curve (ROC) was of 0.007 (CI 95%, from 0.572 to 0.851). Using a standard
cut-off value of >4.0/mm2 for cluster density, early relapse was detected with a sensitivity of 51.5% and a specificity
of 85.7%.
Multivariate Cox regression analysis revealed that clustered precursor is an independent risk factor for early relapse
(Adjusted HR: 0.325, 95% CI: 0.156-0.679, p = 0.003).
Conclusions: Cumulatively, clustered precursors in BM sections during CR may serve as an independent risk factor
of early relapse and poor outcome for AML patients in cluster density > 4.0/mm2 in sections. Early aggressive
interventions are needed to prevent hematologic relapse.
Keywords: Bone marrow, Biopsy, Relapse, Acute myeloid leukemiaIntroduction
In leukemia, the leading cause of treatment failure is dis-
ease relapse. Salvage treatments for relapsed patients fre-
quently lead to dismal outcomes including low levels of
complete remission (CR) and short overall survival (OS)
times [1-4]. Hitherto, the traditional approach to assess
treatment response and follow-up has relied on counting
blast cells in bone marrow (BM) smears. BM smears,
however, may occasionally be diluted by sinusoidal blood
and subsequently cannot provide reliable information on
treatment response and fail to judge early relapse [5].
It may even be inferior to the BM imprint found in* Correspondence: shijun7@hotmail.com
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reproduction in any medium, provided the ortrephine biopsy for the evaluation of cellularity, at least
according to a recent report [6]. In addition, BM aspir-
ation only provides information on cellularity and lacks
other information such as cellular localization and mi-
croenvironmental structure. BM biopsy sections might
compensate for these shortcomings [7].
Similar to the observations made for cell numbers, cell
localization might also provide important information
applicable to disease diagnosis and perhaps prognosis as-
sessment. In normal human subjects, precursors are rare
and are found localized near the endosteum, and consist
of 1-2 cells. In some cases of myelodysplasia syndrome
(MDS), immature precursors might be located in the
intertrabecular region and occasionally aggregate as
clusters which are of 3 ~ 5 cells, such clusters were
initially defined as abnormal localization of immatureThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sented in high-risk MDS patients and the delay prior to
transforming to acute myeloid leukemia (AML) was much
shorter as compared with ALIP-negative MDS patients
[8-10]. It thus suggested that abnormal localization of
precursors could assist in the assessment of patient
prognosis.
In the present study, we found during CR of AML pa-
tients, there existed clustered precursors consisting of 3
to 5 cells in the intertrabecular region. Since they were
morphologically and anatomically analogous to ALIP in
MDS, we defined them as ALIP-like clusters. The pre-
cise information that histological data provides during
CR is largely unknown. Here, we extended our investiga-
tions to explore a histological relapse indicator by com-
paring the frequency of ALIP-like clusters between
relapse and no-relapse cases.
Materials and methods
Patients
Between December 2004 and February 2013, 115 pa-
tients with de novo AML were admitted to the
Hematology Department of Shanghai Sixth People’s
Hospital, China. Patients were diagnosed according to
the FAB classification. CR and relapse were diagnosed
according to Cheson et al. [11]. Those patients who did
not receive stem cell transplantation were enrolled in
this study. Cases were excluded from the study if they:
(a) lacked complete clinical data; (b) presented with
other diseases that might impact on chemotherapy; or
(c) died because of other disease but not of leukemia.
With those exclusion criteria, 60 patients were enrolled
in this study. For induction therapies, AML patients
were treated with one anthracycline agent (daunorubi-
cin, idarubicin, epirubicin or mitoxantrone at a daily
dosage of (40–60) mg/m2, 7-8 mg/m2, (60–90) or
(8–10) mg/m2, respectively) for 3 days and cytarabine at
(100–150) mg/m2 daily for 7 days. For consolidation
therapies, AML patients received up to 6 cycles of in-
duction therapies including one alternative anthracy-
cline with similar dosage mentioned above. All trephine
biopsies and administrations were performed after hav-
ing obtained informed consent. This study was ap-
proved by the institutional Ethics Committees of our
hospital and conducted in accordance with the ethical
guidelines of the Declaration of Helsinki. First check-up
post induction was assessed by bone marrow biopsy on
day 21–28 post induction. Concerning the physical con-
dition of the patients, the biopsies might be retarded
until peripheral blood recovery. During CR, BM biop-
sies were routinely performed before every consolida-
tion therapies. After consolidation therapies, bone
marrow was surveilled by biopsies every 3 months in
the first year and every 6 months in the second year.BM sections and smears from the patients were assayed
under paired analysis from the time of diagnosis to the
follow-up. Cases in CR were divided into relapse and
no-relapse groups according to patients relapsed or not
during the follow-up. The pathologists who examined
the BM samples were not participant of this study and
were innocent about the group situation. Clinical out-
come was assessed by relapse-free survival (RFS) and
overall survival (OS).
Determination of the distance from precursors to
endosteum and precursor density on BM sections
BM biopsy samples were collected from AML patients
during CR and fixed in Bouin fixative. Dehydration was
performed by exposing specimens to ascending con-
centrations of ethanol. All samples were embedded in
Hemapun865 plastic. The component of the plastic and
the detailed embedding technique had been previously
described [12]. BM sections of 3 μm thickness were
stained with haematoxilin-giemsa-acid fuchsin (HGF) for
visualization of immature precursor cells. Specimens
were observed by using of optical microscope imaging
system (Olympus, Tokyo, Japan). Precursors were sub-
grouped into single, double and clustered cells that con-
sisted of ≥ 3 precursors. For every case, sections were
observed randomly by 10 fields of view with × 400 magni-
fication. For detection of the precise distance between
precursors and endosteum, computer image processing
technology was performed [13]. The distance detected by
computer as pixel was transferred into μm by the algo-
rithm of 1 pixel = 0.2 μm. For detection of the density of
precursors found in BM sections, a hemocytometer was
used, wherein the 16 smallest square lattices were set as
1 mm2.
Immunohistochemical (IHC) staining
To study the cellularity of ALIP-like clusters, IHC stain-
ing was performed. The formalin-fixed, EDTA (PH 7.4)
decalcificated and paraffin-embedded bone marrow tis-
sues were cut at a section thickness of 3 μm. The stain-
ing procedure was done in accord with the instructions
provided with an UltraVision Quanto Detection System
HRP DAB kit’s (Thermo Scientific, TL-060-QHD, CA,
USA). In brief, sections were deparaffinized in xylene
and rehydrated by exposure of the specimens to graded
ethanol. Antigen retrieval was performed by sodium cit-
rate buffer with pH 6.0 at 90°C for 15 min. Mouse anti-
human CD34 Class II monoclonal antibody (1:100 diluted,
M7165,Dako, Glostrup, Denmark), rabbit anti-human
CD117 polyclonal antibody (1:200 diluted, A4502, Dako,
CA, USA), and mouse anti-human myeloperoxidase
(MPO) antibody (1:8 diluted, R-0405, Changdao, Shanghai,
China) were incubated at 4°C over night. Horseradish
peroxidase (HRP) labeled secondary antibody and the
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to the kit’s instructions. Then sections were viewed under
the light microscope (Olympus, Tokyo, Japan).
Statistical analysis
Mann–Whitney U test was applied to compare the dens-
ity of precursors between the relapse and no-relapse
cases and their distance to endosteum in every cell
group. Chi-square test and Fisher’s exact test were used
for categorical data. A receiver operating characteristic
curve (ROC) analysis was performed and the corre-
sponding area under the curve (AUC) was calculated to
determine the value of the precursor density in predict-
ing a recurrence. Survival curves were constructed using
the Kaplan–Meier method and the log-rank test was
used to test the difference in RFS and OS between cases
with different densities of ALIP-like clusters. RFS was
defined as the time between diagnosis and the onset of
the first relapse, and OS was defined as the time be-
tween diagnosis and the occurrence of death or when
lost to follow-up. Cox proportional hazard regression
was used to model the RFS. The data were described as
mean ± standard deviation (SD), P values ≤0.05 were
considered statistically significant. All statistical analyses
were conducted by using the SPSS 18.0 software pro-
gram (Statistical Package for Social Science, SPSS Inc.
Chicago, IL., USA).
Results
Characteristics of the patients
Ages of patients in the relapse group and no-relapse
group were (51.85 ± 17.96) years and (49.86 ± 16.96)
years respectively. The ratios of male/female in the two
groups were 24/15 and 10/11 respectively (Table 1).
There were no statistical differences in age, sex and FAB
subtypes between the two groups.
Cellularity and localization of precursors in BM histologcal
sections during CR of AML
During CR, there exited single, double and clustered
precursors in BM sections (Figure 1A) .The exact dis-
tances from the center of the precursors or clusters to
the endosteum were detected by computer processing
image. Clustered precursors were located further than
single precursors and double precursors (P < 0.0001 and
P = 0.0002, respectively, Figure 1B) and consequently in
the intertrabecular region. The distance to the endos-
teum between single and double precursors showed no
significant difference (P = 0.468, Figure 1B).
Density of ALIP-like clusters during CR is associated with
relapse risk
As shown in Figure 2a, the density of single and double
precursors in relapse group increased in trace level butindicated no statistical significance when compared with
no-relapse group (P = 0.0651 and 0.0897 respectively).
However, clustered precursors in relapse patients were
significant higher than those in no-relapse patients
(P = 0.0075). In ROC analysis of recurrent prediction,
single, double and clustered precursors resulted in an
AUC of 0.551, 0.573, and 0.711, respectively (Figure 2B)
and with P value 0.515, 0.352 and 0.007, respectively.
This observation suggested that the strongest predictor
for leukemic relapse was clustered precursors, and the
threshold value of the cluster density was 4.0/mm2 to
achieve the maximum sum of both sensitivity and speci-
ficity (Table 2). Subsequently, in order to evaluate the
sensitivity of histological appearance in relapse predic-
tion, time-point of histological relapse (cluster density >
4.0/mm2) and hematologic relapse were compared. As a
result, the median time from histologic relapse to
hematologic relapse was 8 months (Figure 2C). Add-
itionally,the probability of RFS and OS were compared
between cases with cluster density > 4.0/mm2 and those
less than 4.0/mm2. As shown in Figure 3A-B, there
was a poorer prognosis in RFS (P = 0.0011) and OS
(P = 0.045) for cases with cluster density > 4.0/mm2.
Prognostic assessment of known clinical parameters
In the univariate and multivariate Cox regression model,
only the factor of cluster density > 4.0/mm2 was associ-
ated with higher relapse risk (P = 0.002 and 0.003, re-
spectively Table 3). Other candidate prognostic factors
including bone marrow precursors, peripheral white
blood cells and age, were not associated with higher re-





























Figure 1 Distances to the endosteum among different groups of cells. (A) Representative histological section from an AML patient in CR.
Solid arrows indicated single precursor, arrow head indicated double precursors, and hollow arrow indicated clustered precursor. Dashed red line
highlighted the endosteal surface. Staining of sections was done by haematoxilin-giemsa acid fuchsin (HGF), and observed at × 400 magnification.
(B) Single and double precursors were located near the endosteum and there was no statistical difference between the two groups. By contrast,
the clustered precursors were located further from endosteum than single and double precursors.
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precursors
To clarify whether ALIP-like cluster were composed of
immature myeloid precursors, assay of staining for MPO














































Figure 2 ALIP-like clusters during CR in AML patients were considere
group. (A) Densities of single, double, and clustered precursors were highe
of relapse from single, double and clustered precursors. This analysis showe
AUC = 0.711. AUC: Area under curve. (C) The median time from histologic rand CD117 were chosen for staining immature precur-
sors. As a result, all ALIP-like clusters were MPO posi-
tive. However, the expression of CD34 and CD117 was
shown to be variable. As shown in Figure 4A, precursors
in some ALIP-like clusters expressed both CD34 andB
p
d the best indicator of early relapse among the three precursor
r in the pre-relapse cases. (B) showing ROC analysis for the prediction
d that ALIP-like clusters mostly favored the prediction of relapse with
elapse to overt hematologic relapse.
Table 2 Sensitivity and specificity of ALIP-like cluster
density in identifying relapse risk according to ROC
curve analysis











*The threshold value of cluster density in BM sections for predicting relapse.
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expressed neither (Figure 4B).
Discussion
Since single and double precursors are observed in
healthy human BM sections and are located near endos-
teum, we found it intriguing to know how the precursors
and especially ALIP-like clusters were located in AML
in CR. In this setting, we detected the distances between
precursors and the endosteum in BM sections by com-
puter image processing technology. As a result, single
and double precursors in CR of AML were also observed
near the endosteum. ALIP-like clusters, however, were
located farther from the endosteum. Furthermore, IHC
assays showed that these clusters were of myeloid
lineage, and strongly supported the sense that the clus-
ters were ALIP-like.
We hypothesized that similar with the prognostic
value of ALIP in MDS, ALIP-like cluster in CR of AML
patients should also be considered as a prognostic factor.































Figure 3 Exceeding ALIP-like cluster density (>4/mm2) indicated poor
cases with exceeding ALIP-like cluster density (>4/mm2) carried poorer outrelapse group than in no-relapse group. However, it was
interesting that frequencies of single and double precur-
sors were not statistically higher in relapse cases than in
no-relapse cases. Since clustered precursors are only ob-
served in BM sections from malignant diseases (MDS
and CR of AML) or some benign disease with impaired
BM, such as BM necrosis and stromal alterations in sys-
temic lupus erythematosus patients [14], but not in nor-
mal BM sections, we speculate that in CR of AML,
clustered precursors, but not single and double precur-
sors, are more characteristic for malignant hematopoiesis
in BM sections, and it is thus considered that only ALIP-
like cluster could be acted as relapse predictor. With ROC
analysis, it testified that ALIP-like clusters were most fa-
vorable for relapse prediction than single and double pre-
cursors. We subsequently established that cluster density
of 4.0/mm2 as the most optimal threshold value with the
most predictive power and it might predict relapse with 8
months earlier than hematologic relapse. Survival analysis
further verified that cases with histologic relapse carried a
poorer clinical outcome in both RFS and OS. To de-
termine whether ALIP-like clusters are an independent
predict marker at high risk of early relapse, Cox propor-
tional hazards model was performed. In this model, it
indicated that ALIP-like cluster was the independent risk
factor for assessing early relapse. Here, we propose that in
BM sections, cluster density more than 4/mm2 during
hematological remission to be referred to as histologic re-
lapse, and more aggressive adjuvant treatment is needed
to prevent hematologic relapse.
Our observations showed that single and double precur-
sors were located near the endosteum, while ALIP-like
clusters were in intertrabecular region. This is analogous
with a recent study that showed that single normal
hematopoietic stem cells (HSC) were located close to the
endosteum. However, more mature precursors were lo-
cated farther away from the endosteum and expanded to
clusters [15]. Likewise, chemo-resistant leukemic stem
cells (LSC) were prominently located near the endosteumB



























er survival. Contrast to cases with <4/mm2 of ALIP-like cluster density,
come in both RFS (A) and OS (B).
Table 3 Cox regression analysis of RFS in AML patients during CR
Variables Univariate analysis Multivariate analysis
HR 95% CI P value Adjusted HR 95% CI P value
ALIP-like cluster* 0.353 0.183-0.680 0.002 0.325 0.156-0.679 0.003
BMP 1.381 0.408-4.670 0.604 2.358 0.598-9.290 0.220
PWBC 1.011 1.000-1.023 0.051 1.008 0.997-1.020 0.164
Age 1.008 0.990-1.026 0.408 1.001 0.980-1.022 0.944
Abbreviations: BMP Bone marrow precursors, HR hazard ratio, CI confidence interval, PWBC peripheral white blood cell.
*ALIP-like cluster density > 4/mm2 versus < 4/mm2.
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setting, we hypothesized that ALIP-like clusters evolved
from LSC harboring at sites near the endosteum, while
under conditions of administration retrieval, LSC might
exhibit differentiation under the influence of some cyto-
kine regulators such as vascular endothelial cell growth
factor [17-19] and insulin-like growth factor [20]. Under
those situations, the progeny cells migrate toward the
intertrabecular region [21]. In the context of this hy-
pothesis, ALIP-like clusters might be heterogeneous and
hierarchical with more mature population located in inter-
trabecular region. Contrarily, more immature population
might be located closer to the endostreum. IHC staining
indicated that the progeny cells shared variable immuno-
phenotype, wherein some sub-populations were CD34/
CD117 positive, while the others are negative. These ob-
servations supported that analogous with LSC, the daugh-





Figure 4 ALIP-like clusters are of heterogeneous myeloid precursors.
CD34 and CD117 (A). However, other clusters expressed neither CD34 nor
indicated ALIP-like clusters.In this current study, we propose that at a value of
greater than 4.0/mm2 of ALIP-like cluster density in BM
sections within hematologic remission is a strong inde-
pendent prognostic factor for AML after achieving a
complete remission, and consider it as an indication of
histologic relapse and early interventions might be
considered as a pre-requisite in histological relapse to
improve eventual clinical outcomes. Here, we suggest BM
biopsies should be considered while other minimal residual
disease measurements such as reverse transcription-
polymerase chain reaction (RT-PCR), flow cytometer, etc.
are not available. Nonetheless, there are some limitations
in this study. Firstly, cytogenetic and molecular marker as-
says are not routinely performed at this hospital, compari-
son and combination with other MRD measurements such
as RT-PCR, flow cytometer, etc. [22,23] are lacking.
Secondly, we could not exclude the influence of cyto-
genetic subtypes on relapse and clinical outcome. A
further prospective blinded study is required to assessCD117
CD117
All ALIP-like clusters expressed MPO. Some clusters expressed both
CD117 (B). Sections were observed at × 1000 magnification. Arrows
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lapse prediction.
Conclusion
Taken together, in this retrospective study, we found
during CR of AML patients, except for single and double
precursors, there existed clustered precursors of 3 ~ 5
cells. The clustered precursors are morphologically and
anatomically analogous to ALIP in MDS. Similar with
the prognostic value of ALIP in MDS, these ALIP-like
clusters in BM sections during CR of AML could also be
used as an independent predictor of early relapse and
poor outcome for AML patients. Finally, we proposed
that while ALIP-like cluster density increased to over
the threshold of 4.0/mm2, although in hematological re-
sponse, urgent interference should be needed to prevent
early recurrence and consequently improve the OS.
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